by B2i | Nov 2, 2022 | Press Releases
ROCKVILLE, Md., Nov. 1, 2022 –Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced the...
by B2i | Sep 20, 2022 | Press Releases
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md., Sept. 20, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of...
by B2i | Sep 15, 2022 | Press Releases
Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md., Sept. 15, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company, announced today that it has been awarded patents in the...
by B2i | Sep 6, 2022 | Press Releases
ROCKVILLE, Md., Sept. 6, 2022 — Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT) while reducing side...
by B2i | Aug 31, 2022 | Press Releases
Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effectsROCKVILLE, Md., Aug. 31, 2022 — Shuttle Pharmaceuticals Holdings,...
